Literature DB >> 23571453

Malignant pericardial effusion.

I Burazor1, M Imazio, G Markel, Y Adler.   

Abstract

Malignant pericardial effusion is a common and serious manifestation in malignancies. The origins of the malignant process include solid tumors or hematological malignancies, while primary neoplasms of the pericardium are less common. In the oncological patient, pericardial effusion may develop by several different mechanisms, namely by direct or metastatic spread of the primary process or as a complication of antineoplastic therapies. In some cases, pericardial effusion may be the first manifestation of the disease, and that is why malignancy must be excluded in every case of an acute pericardial disease with cardiac tamponade at presentation, rapidly increasing pericardial effusion and an incessant or recurrent course. Thus, the definite differentiation of malignant pericardial effusion and rapid diagnosis are of particular therapeutic and prognostic importance. Management of these patients is multidisciplinary and requires team work, but at present there is a need for further research. An individual treatment plan should be established, taking into account cancer stage, the patient's prognosis, local availability and experience. In emergency cases with cardiac tamponade or significant effusion, initial relief can be obtained with pericardiocentesis. Despite the magnitude of this serious problem, little progress has been made in the treatment of pericardial effusion secondary to malignant disease.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23571453     DOI: 10.1159/000348559

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  21 in total

1.  Recurrent cardiac tamponade: an initial presentation of lung adenocarcinoma.

Authors:  Aditi Kumar; Amar Puttanna
Journal:  BMJ Case Rep       Date:  2014-05-21

2.  Sudden death due to cardiac tamponade from malignant pericardial involvement by metastatic lung cancer.

Authors:  Robert Cassady; Joseph A Prahlow
Journal:  Forensic Sci Med Pathol       Date:  2014-10-19       Impact factor: 2.007

3.  The value of the new scoring system for predicting neoplastic pericarditis in the patients with large pericardial effusion.

Authors:  M Szturmowicz; A Pawlak-Cieślik; A Fijałkowska; J Gątarek; A Skoczylas; M Dybowska; K Błasińska-Przerwa; R Langfort; W Tomkowski
Journal:  Support Care Cancer       Date:  2017-03-03       Impact factor: 3.603

4.  Pericarditis as a Marker of Occult Cancer and a Prognostic Factor for Cancer Mortality.

Authors:  Kirstine Kobberøe Søgaard; Dóra Körmendiné Farkas; Vera Ehrenstein; Krishnan Bhaskaran; Hans Erik Bøtker; Henrik Toft Sørensen
Journal:  Circulation       Date:  2017-06-29       Impact factor: 29.690

5.  A Lung Cancer Patient With Respiratory Insufficiency and Hemodynamic Instability.

Authors:  Leon L Chen; Meaghen Finan; Elena Mead; Neil A Halpern
Journal:  Chest       Date:  2018-03       Impact factor: 9.410

6.  Chronic GvHD-associated serositis and pericarditis.

Authors:  J T Leonard; L F Newell; G Meyers; B Hayes-Lattin; J Gajewski; S Heitner; S Nonas; B Allen; A Stentz; R Frires; R T Maziarz; S G Holtan
Journal:  Bone Marrow Transplant       Date:  2015-05-11       Impact factor: 5.483

7.  Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion.

Authors:  Danielle El Haddad; Cezar Iliescu; Syed Wamique Yusuf; William Nassib William; Tarif H Khair; Juhee Song; Elie N Mouhayar
Journal:  J Am Coll Cardiol       Date:  2015-09-08       Impact factor: 24.094

8.  Cardiac Tamponade as a Manifestation of Clear Cell Renal Cell Carcinoma.

Authors:  María Teresa Calzada; Ignacio Boira; Eusebi Chiner; Violeta Esteban; José Norberto Sancho
Journal:  Cureus       Date:  2021-06-15

Review 9.  Management of Malignant Pericardial Effusion.

Authors:  Mary Petrofsky
Journal:  J Adv Pract Oncol       Date:  2014 Jul-Aug

10.  Pericardial Effusions in Patients With Cancer: Anesthetic Management and Survival Outcomes.

Authors:  Casey M Chai; Kenneth Seier; Kay See Tan; Iris Chu; James M Isbell; Gregory W Fischer; Anoushka M Afonso
Journal:  J Cardiothorac Vasc Anesth       Date:  2020-08-26       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.